Logo

PTIXW

Protagenic Therapeutics, Inc.

PTIXW

Protagenic Therapeutics, Inc. • NASDAQ
$0.03 ▲ 3.54% (+0.00)
Market Cap $1.83 M
52w High $0.03
52w Low $0.02
Dividend Yield 0%
P/E 0
Volume 4.43K
Outstanding Shares 68.20M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.114M ▼ $-869.496K ▲ 0% $-0.47 ▲ $-1.114M ▲
Q2-2025 $0 $2.332M ▲ $-5.058M ▼ 0% $-1.37 ▲ $-4.806M ▼
Q1-2025 $0 ▲ $1.448M ▼ $-1.44M ▲ 0% ▼ $-2.75 ▼ $-1.436M ▲
Q4-2024 $-25.143K ▼ $1.643M ▲ $-1.554M ▼ 6.181K% ▲ $-0.24 ▼ $-1.541M ▼
Q3-2024 $0 $652.066K $-641K 0% $-0.14 $-628K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.722M ▼ $2.145M ▼ $9.703M ▼ $-7.559M ▼
Q2-2025 $4.096M ▲ $6.488M ▲ $10.462M ▲ $-3.974M ▼
Q1-2025 $872.96K ▼ $988.65K ▼ $1.077M ▲ $-88.329K ▼
Q4-2024 $1.838M ▲ $1.956M ▲ $942.759K ▲ $1.013M ▲
Q3-2024 $1.056M $1.508M $789.32K $719.007K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.487M ▲ $-1.495M ▼ $943.18K $4.305M ▼ $1.849M ▼ $-1.495M ▼
Q2-2025 $-5.058M ▼ $-1.167M ▼ $943.18K ▲ $4.423M ▲ $4.082M ▲ $-1.167M ▼
Q1-2025 $-1.44M ▲ $-1.068M ▼ $0 $102.519K ▼ $-965.509K ▼ $-1.068M ▼
Q4-2024 $-1.554M ▼ $-819.791K ▼ $0 $1.602M ▲ $782.664K ▲ $-819.791K ▼
Q3-2024 $-640.785K $-185.661K $0 $316.959K $131.209K $-185.661K

Five-Year Company Overview

Income Statement

Income Statement Protagenic has been a pure research-stage biotech so far: it has not generated any product or licensing revenue over the past several years. All activity runs on spending for research, development, and corporate overhead, which leads to recurring annual losses. Per‑share losses have been consistently negative, reflecting that the business is still in the build‑out and testing stage rather than anywhere near commercial scale. There is no sign yet of an economic engine from operations; the value story is entirely about future potential, not current earnings power.

Balance Sheet

Balance Sheet The balance sheet appears extremely thin, with only a small base of assets and equity and no reported financial debt in the historical data. That suggests a very lean, under‑capitalized platform that relies heavily on outside funding to keep research moving. The company’s own disclosures about potential Nasdaq delisting for low equity reinforce the picture of a fragile financial position. The lack of debt is a positive in the sense that there are no large lenders to satisfy, but the limited asset base leaves little cushion if funding or market conditions worsen.

Cash Flow

Cash Flow Reported cash flow figures are effectively flat, which likely reflects the tiny scale and rounding rather than a truly cash‑neutral business. In practice, as an early‑stage biotech with no revenue, the company almost certainly has ongoing cash burn to pay for trials, staff, and public company costs. That spending is funded mainly through selling equity or related instruments, not from operations. The move to a “virtual” operating model is a clear signal that management is trying to stretch limited cash by cutting fixed costs, but it also underlines how tight liquidity appears to be.

Competitive Edge

Competitive Edge On the scientific side, Protagenic has carved out a niche in stress‑related brain disorders and broader central nervous system conditions, an area with big unmet medical needs and room for innovation. Its lead program targets stress pathways in a novel way, and the merger with Phytanix adds a broader pipeline spanning epilepsy, mood disorders, and obesity. This gives the company a more diversified scientific story and access to teams with past success in cannabinoid‑based drugs. However, commercially it remains very small, pre‑revenue, and up against far larger pharmaceutical and biotech players with deeper pockets, established sales forces, and their own CNS and obesity pipelines. As a result, its scientific differentiation is promising, but its market power is currently limited and heavily dependent on successful data and partnerships.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. The lead candidate, PT00114, uses a first‑in‑class peptide approach aimed at the biological roots of stress rather than just symptoms. Early human safety data are encouraging, and the program is moving through Phase 1 with a goal of reaching Phase 2, where real effectiveness will be tested. The Phytanix merger adds several preclinical assets in epilepsy, psychiatric conditions, and obesity, plus modified stilbenoid compounds with anticonvulsant potential. Together, this forms a more rounded CNS‑focused R&D platform with expanded patent coverage and a team that has worked on approved cannabinoid drugs before. The flip side is that almost all of this pipeline is early‑stage, years away from possible approval, and highly exposed to clinical and regulatory setbacks. Progress will hinge on both scientific success and the company’s ability to keep funding this research through a period of financial strain.

Summary

Protagenic Therapeutics (PTIX/PTIXW) is a very early‑stage, high‑risk biotech focused on novel treatments for stress‑related and other brain and metabolic disorders. The story is dominated by science and future potential: no revenue today, recurring losses, and a very thin balance sheet that has already led to concerns about Nasdaq listing compliance. The recent merger with Phytanix broadens the pipeline and brings experienced drug developers and new intellectual property, improving the long‑term scientific opportunity but also adding integration complexity. In the near term, the key swing factors are: securing enough capital to keep programs moving, successfully integrating the new assets and team, and delivering clean safety and early efficacy data in upcoming trials. Until there is clearer evidence from clinical results and a more robust financial base, the company’s outlook remains highly speculative and dependent on successful execution against significant scientific and funding risks.